Clostridioides difficile infection, recurrence and the associated healthcare consumption in Sweden between 2006 and 2019: a population-based cohort study.
Humans
Female
Male
Clostridium Infections
/ epidemiology
Sweden
/ epidemiology
Middle Aged
Aged
Adult
Recurrence
Cohort Studies
Young Adult
Adolescent
Aged, 80 and over
Clostridioides difficile
Hospitalization
/ statistics & numerical data
Length of Stay
/ statistics & numerical data
Cross Infection
/ epidemiology
Incidence
Child
Child, Preschool
Infant
Patient Acceptance of Health Care
/ statistics & numerical data
Clostridioides difficile
Burden
Health-economic
Healthcare consumption
Real world evidence
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
received:
14
12
2023
accepted:
29
04
2024
medline:
4
5
2024
pubmed:
4
5
2024
entrez:
3
5
2024
Statut:
epublish
Résumé
Clostridioides difficile infection (CDI) causes a major burden to individuals and society, yet the impact may vary depending on age, sex, underlying comorbidities and where CDI was acquired (hospital or community). This Swedish nationwide population-based cohort study (2006-2019) compared all 43,150 individuals with CDI to their 355,172 matched controls (first year and entire follow-up). Negative binomial regression models compared the cumulated length of stay, number of in-hospital admissions, outpatient visits and prescriptions after the first CDI episode expressed as incidence rate ratios (IRR) and 95% confidence intervals for the entire follow-up. Overall, 91.6% of CDI cases were hospital acquired, and 16.8% presented with recurrence(s); 74.8%of cases were ≥ 65 years and 54.2% were women. Compared to individuals without CDI, in-hospital stay rates were 18.01 times higher after CDI (95% CI 17.40-18.63, first-year: 27.4 versus 1.6 days), 9.45 times higher in-hospital admission (95% CI 9.16-9.76, first-year: 2.6 versus 1.3 hospitalisations), 3.94 times higher outpatient visit (95% CI 3.84-4.05, first-year: 4.0 versus 1.9 visits) and 3.39 times higher dispensed prescriptions rates (95% CI 3.31-3.48, first-year: 25.5 versus 13.7 prescriptions). For all outcomes, relative risks were higher among the younger (< 65 years) than the older (≥ 65 years), and in those with fewer comorbidities, but similar between sexes. Compared to those without recurrence, individuals with recurrence particularly showed a higher rate of hospital admissions (IRR = 1.18, 95% 1.12-1.24). Compared to community-acquired CDI, those with hospital-acquired CDI presented with a higher rate of hospital admissions (IRR = 7.29, 95% CI 6.68-7.96) and a longer length of stay (IRR = 7.64, 95% CI 7.07-8.26). CDI was associated with increased health consumption in all affected patient groups. The majority of the CDI burden could be contributed to hospital-acquired CDI (~ 9/10), older patients (~ 3/4) and those with multiple comorbidities (~ 6/10 Charlson score ≥ 3), with 1/5 of the total CDI burden contributed to individuals with recurrence. Yet, relatively speaking the burden was higher among the younger and those with fewer comorbidities, compared to their peers without CDI.
Sections du résumé
BACKGROUND
BACKGROUND
Clostridioides difficile infection (CDI) causes a major burden to individuals and society, yet the impact may vary depending on age, sex, underlying comorbidities and where CDI was acquired (hospital or community).
METHODS
METHODS
This Swedish nationwide population-based cohort study (2006-2019) compared all 43,150 individuals with CDI to their 355,172 matched controls (first year and entire follow-up). Negative binomial regression models compared the cumulated length of stay, number of in-hospital admissions, outpatient visits and prescriptions after the first CDI episode expressed as incidence rate ratios (IRR) and 95% confidence intervals for the entire follow-up.
RESULTS
RESULTS
Overall, 91.6% of CDI cases were hospital acquired, and 16.8% presented with recurrence(s); 74.8%of cases were ≥ 65 years and 54.2% were women. Compared to individuals without CDI, in-hospital stay rates were 18.01 times higher after CDI (95% CI 17.40-18.63, first-year: 27.4 versus 1.6 days), 9.45 times higher in-hospital admission (95% CI 9.16-9.76, first-year: 2.6 versus 1.3 hospitalisations), 3.94 times higher outpatient visit (95% CI 3.84-4.05, first-year: 4.0 versus 1.9 visits) and 3.39 times higher dispensed prescriptions rates (95% CI 3.31-3.48, first-year: 25.5 versus 13.7 prescriptions). For all outcomes, relative risks were higher among the younger (< 65 years) than the older (≥ 65 years), and in those with fewer comorbidities, but similar between sexes. Compared to those without recurrence, individuals with recurrence particularly showed a higher rate of hospital admissions (IRR = 1.18, 95% 1.12-1.24). Compared to community-acquired CDI, those with hospital-acquired CDI presented with a higher rate of hospital admissions (IRR = 7.29, 95% CI 6.68-7.96) and a longer length of stay (IRR = 7.64, 95% CI 7.07-8.26).
CONCLUSION
CONCLUSIONS
CDI was associated with increased health consumption in all affected patient groups. The majority of the CDI burden could be contributed to hospital-acquired CDI (~ 9/10), older patients (~ 3/4) and those with multiple comorbidities (~ 6/10 Charlson score ≥ 3), with 1/5 of the total CDI burden contributed to individuals with recurrence. Yet, relatively speaking the burden was higher among the younger and those with fewer comorbidities, compared to their peers without CDI.
Identifiants
pubmed: 38702635
doi: 10.1186/s12879-024-09364-3
pii: 10.1186/s12879-024-09364-3
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
468Subventions
Organisme : Ferring Pharmaceuticals
ID : Research collaboration agreement
Organisme : Ferring Pharmaceuticals
ID : Research collaboration agreement
Organisme : Ferring Pharmaceuticals
ID : Research collaboration agreement
Informations de copyright
© 2024. The Author(s).
Références
Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care–associated infections in US hospitals. N Engl J Med. 2018;379(18):1732–44.
doi: 10.1056/NEJMoa1801550
pubmed: 30380384
pmcid: 7978499
Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC infectious diseases. 2021;21(1):456 PubMed PMID: 34016040. Pubmed Central PMCID: PMC8135979. Epub 2021/05/22. eng.
doi: 10.1186/s12879-021-06147-y
pubmed: 34016040
pmcid: 8135979
Borren NZ, Ghadermarzi S, Hutfless S, Ananthakrishnan AN. The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PloS one. 2017;12(5):e0176797.
doi: 10.1371/journal.pone.0176797
pubmed: 28463987
pmcid: 5413003
Ghia CJ, Waghela S, Rambhad GS. Systematic Literature Review on Burden of Clostridioides difficile Infection in India. Clinical pathology (Thousand Oaks, Ventura County, Calif). 2021;14:2632010x211013816 PubMed PMID: 34104883. Pubmed Central PMCID: PMC8170333. Epub 2021/06/10. eng.
pubmed: 34104883
pmcid: 8170333
Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407. Epub 2019/01/04. eng.
Boven A, Vlieghe E, Engstrand L, Andersson FL, Callens S, Simin J, Brusselaers N. Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study. Clin Microbiol Infect. 2023:S1198-743X(23):00315–4. https://doi.org/10.1016/j.cmi.2023.07.008 . Epub ahead of print.
Yu H, Flaster N, Casanello AL, Curcio D. Assessing risk factors, mortality, and healthcare utilization associated with Clostridioides difficile infection in four Latin American countries. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2021;25(1):101040.
doi: 10.1016/j.bjid.2020.11.005
pubmed: 33290727
Malone DC, Armstrong EP, Gratie D, Pham SV, Amin A. A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections. Antimicrobial stewardship & healthcare epidemiology : ASHE. 2023;3(1):e17.
doi: 10.1017/ash.2022.369
pmcid: 9879868
Reveles KR, Yang M, Garcia-Horton V, Edwards ML, Guo A, Lodise T, et al. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis. Advances in therapy. 2023;40(7):3104–34 PubMed PMID: 37210680. Pubmed Central PMCID: PMC10272265. Epub 2023/05/21. eng.
doi: 10.1007/s12325-023-02498-x
pubmed: 37210680
pmcid: 10272265
Wingen-Heimann SM, Davies K, Viprey VF, Davis G, Wilcox MH, Vehreschild M, et al. Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023;29(5):651.e1-e8 PubMed PMID: 36586512. Epub 2023/01/01. eng.
doi: 10.1016/j.cmi.2022.12.019
pubmed: 36586512
Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC infectious diseases. 2016;16(1):447 PubMed PMID: 27562241. Pubmed Central PMCID: PMC5000548. Epub 2016/08/27. eng.
doi: 10.1186/s12879-016-1786-6
pubmed: 27562241
pmcid: 5000548
Nanwa N, Sander B, Krahn M, Daneman N, Lu H, Austin PC, et al. A population-based matched cohort study examining the mortality and costs of patients with community-onset Clostridium difficile infection identified using emergency department visits and hospital admissions. PloS one. 2017;12(3):e0172410. PubMed PMID: 28257438. Pubmed Central PMCID: PMC5336215. Epub 2017/03/04. eng.
doi: 10.1371/journal.pone.0172410
pubmed: 28257438
pmcid: 5336215
Shorr AF, Zilberberg MD, Wang L, Baser O, Yu H. Mortality and Costs in Clostridium difficile Infection Among the Elderly in the United States. Infect Control Hosp Epidemiol. 2016;37(11):1331–6 PubMed PMID: 27572289. Epub 2016/10/22. eng.
doi: 10.1017/ice.2016.188
pubmed: 27572289
Braae UC, Møller FT, Ibsen R, Ethelberg S, Kjellberg J, Mølbak K. The Economic Burden of Clostridioides difficile in Denmark: A Retrospective Cohort Study. Frontiers in public health. 2020;8:562957. PubMed PMID: 33324595. Pubmed Central PMCID: PMC7725905. Epub 2020/12/17. eng.
doi: 10.3389/fpubh.2020.562957
pubmed: 33324595
pmcid: 7725905
Son KJ, Kim YA, Park YS. Economic burden attributable to Clostridioides difficile infections in South Korea: a nationwide propensity score-matched study. The Journal of hospital infection. 2022;120:1–8 PubMed PMID: 34774670. Epub 2021/11/15. eng.
doi: 10.1016/j.jhin.2021.10.016
pubmed: 34774670
Kuntz JL, Baker JM, Kipnis P, Li SX, Liu V, Xie Y, et al. Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study. Infect Control Hosp Epidemiol. 2017;38(1):45–52 PubMed PMID: 27760583. Pubmed Central PMCID: PMC5532139. Epub 2016/10/21. eng.
doi: 10.1017/ice.2016.232
pubmed: 27760583
Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care-associated infections: mind your p’s and q’s. Clin Infect Dis. 2010;50(7):1017–21.
doi: 10.1086/651110
pubmed: 20178419
Sahrmann JM, Olsen MA, Stwalley D, Yu H, Dubberke ER. Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023;76(5):809–15 PubMed PMID: 36285546. Pubmed Central PMCID: PMC10226732. Epub 2022/10/27. eng.
doi: 10.1093/cid/ciac841
pubmed: 36285546
Sahrmann JM, Olsen MA, Keller MR, Yu H, Dubberke ER. Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults. Open forum infectious diseases. 2023;10(7):ofad343 PubMed PMID: 37496610. Pubmed Central PMCID: PMC10368308. Epub 2023/07/27. eng.
doi: 10.1093/ofid/ofad343
pubmed: 37496610
pmcid: 10368308
Durovic A, Widmer AF, Frei R, Tschudin-Sutter S. Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations. Infect Control Hosp Epidemiol. 2017;38(8):891–6 PubMed PMID: 28592348. Epub 2017/06/09.
doi: 10.1017/ice.2017.119
pubmed: 28592348
Moreels N, Boven A, Gressani O, Andersson FL, Vlieghe E, Callens S, et al. The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence. The Journal of antimicrobial chemotherapy. 2024;79(3):608–16 PubMed PMID: 38267263. Pubmed Central PMCID: PMC10904719. Epub 2024/01/25.
doi: 10.1093/jac/dkae012
pubmed: 38267263
pmcid: 10904719
Mpakaniye P, Boven A, Callens S, Engstrand L, Vlieghe E, Brusselaers N. Clostridioides difficile recurrence in individuals with and without cancer: a Swedish population-based cohort study. Infection. 2024;52(2):649–60 PubMed PMID: 38407777. Pubmed Central PMCID: PMC10954957. Epub 2024/02/26.
doi: 10.1007/s15010-024-02193-1
pubmed: 38407777
pmcid: 10954957
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and drug safety. 2007;16(7):726–35 PubMed PMID: 16897791. Epub 2006/08/10. eng.
doi: 10.1002/pds.1294
pubmed: 16897791
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. European journal of epidemiology. 2009;24(11):659–67 PubMed PMID: 19504049. Pubmed Central PMCID: PMC2773709.
doi: 10.1007/s10654-009-9350-y
pubmed: 19504049
pmcid: 2773709
Brusselaers N, Lagergren J. The Charlson Comorbidity Index in Registry-based Research. Methods Inf Med. 2017;56(5):401–6 PubMed PMID: 29582935.
doi: 10.3414/ME17-01-0051
pubmed: 29582935
Nelson WW, Scott TA, Boules M, Teigland C, Parente A, Unni S, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. 2021;27(7):828–38 PubMed PMID: 33703939.
pubmed: 33703939
Nordling S, Anttila VJ, Noren T, Cockburn E. The Burden of Clostridium Difficile (CDI) Infection in Hospitals, in Denmark, Finland, Norway And Sweden. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014;17(7):A670 PubMed PMID: 27202459. Epub 2014/11/01. eng.
doi: 10.1016/j.jval.2014.08.2480
pubmed: 27202459
van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls C, Dekkers OM, Kuijper EJ, Keller JJ, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022;28(3):321–31 PubMed PMID: 34655745. Epub 2021/10/17. eng.
doi: 10.1016/j.cmi.2021.09.026
pubmed: 34655745
Singh H, Nugent Z, Walkty A, Yu BN, Lix LM, Targownik LE, et al. Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study. PloS one. 2019;14(11):e0224609. Epub 2019/11/09. eng.
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450 PubMed PMID: 21658213. Pubmed Central PMCID: 3142234. Epub 2011/06/11. eng.
doi: 10.1186/1471-2458-11-450
pubmed: 21658213
pmcid: 3142234
Forsberg L RH, Jacobsson A, Nyqvist K, Heurgren M. Kvalitet och innehåll i patientregistret. Utskrivningar från slutenvården 1964–2007 och besök i specialiserad öppenvård (exklusive primärvårdsbesök) 1997–2007. Stockholm: Socialstyrelsen; 2008. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2009-125-15_200912515_rev2.pdf . Accessed 02 May 2024.
Rizzardi K, Noren T, Aspevall O, Makitalo B, Toepfer M, Johansson A, et al. National Surveillance for Clostridioides difficile Infection, Sweden, 2009–2016. Emerging infectious diseases. 2018;24(9):1617–25 PubMed PMID: 30124193. Pubmed Central PMCID: PMC6106436. Epub 2018/08/21.
doi: 10.3201/eid2409.171658
pubmed: 30124193
pmcid: 6106436
Marra AR, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang HY, et al. Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(1):e1917597. PubMed PMID: 31913488. Pubmed Central PMCID: PMC6991241. Epub 2020/01/09.
doi: 10.1001/jamanetworkopen.2019.17597
pubmed: 31913488
pmcid: 6991241
Socialstyrelsen. The Swedish Prescribed Drug Register 2020 [updated 21–8–202130–9–2021]. Available from: https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-swedish-prescribed-drug-register/ .
Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. 2018;8(7): e021869.
doi: 10.1136/bmjopen-2018-021869
pubmed: 29982219
pmcid: 6042574
Socialstyrelsen;. The Causes of Death Register 2018 [updated 2019–05–29]. Available from: https://www.socialstyrelsen.se/statistik-och-data/register/dodsorsaksregistret/bortfall-och-kvalitet/ .
Cançado GGL, Abreu ES, Nardelli MJ, Serwa P, Brachmann M. A cost of illness comparison for toxigenic Clostridioides difficile diagnosis algorithms in developing countries. Anaerobe. 2021;70:102390. PubMed PMID: 34058377. Epub 2021/06/01. eng.
doi: 10.1016/j.anaerobe.2021.102390
pubmed: 34058377
Yu H, Alfred T, Nguyen JL, Zhou J, Olsen MA. Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023;76(3):e1476–83 PubMed PMID: 35686435. Pubmed Central PMCID: PMC9907506. Epub 2022/06/11. eng.
doi: 10.1093/cid/ciac467
pubmed: 35686435
Wilcox MH, Ahir H, Coia JE, Dodgson A, Hopkins S, Llewelyn MJ, et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. The Journal of antimicrobial chemotherapy. 2017;72(9):2647–56 PubMed PMID: 28633368. Epub 2017/06/22. eng.
doi: 10.1093/jac/dkx174
pubmed: 28633368
Paschos P, Ioakim K, Malandris K, Koukoufiki A, Nayfeh T, Akriviadis E, et al. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Anaerobe. 2021;71:102441. PubMed PMID: 34454094. Epub 2021/08/29. eng.
doi: 10.1016/j.anaerobe.2021.102441
pubmed: 34454094
Richardson M, Erman A, Daneman N, Miller FA, Sander B. Defining the decision problem: a scoping review of economic evaluations for Clostridioides difficile interventions. The Journal of hospital infection. 2022;121:22–31 PubMed PMID: 34813872. Epub 2021/11/24. eng.
doi: 10.1016/j.jhin.2021.11.010
pubmed: 34813872
Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol. 2021;14:17562848211018654 PubMed PMID: 34104214. Pubmed Central PMCID: PMC8170348. Epub 2021/06/10. eng.
doi: 10.1177/17562848211018654
pubmed: 34104214
pmcid: 8170348
Swart N, Sinha AM, Bentley A, Smethurst H, Spencer G, Ceder S, et al. A cost-utility analysis of two Clostridioides difficile infection guideline treatment pathways. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023;29(10):1291–7 PubMed PMID: 37356620. Epub 2023/06/26. eng.
doi: 10.1016/j.cmi.2023.06.018
pubmed: 37356620